Su W, Wang P, Chen H, Li H
Department of Cardiology, Beijing Friendship Hospital, Capital Medical University, No. 95, Yongan Road, Xicheng District, Beijing, 100050, People's Republic of China.
J Endocrinol Invest. 2014 Jun;37(6):559-64. doi: 10.1007/s40618-014-0068-7. Epub 2014 Apr 11.
Relaxin is a pleiotropic hormone owing endogenous antifibrosis effect on numerous organs. We demonstrated relaxin's inhibitive effect on cardiac fibrosis previously.
The aim of this study was to investigate the role of protein kinase C (PKC) β2 in relaxin's action under high glucose conditions.
Cardiac fibroblasts (CFs) were isolated, exposed to high glucose and incubated with recombinant human relaxin (rhRLX). Western blot analysis revealed a relaxin-mediated decrease in total expression and translocation of PKCβ2, showing downregulation of PKCβ2 is involved in relaxin's action. Blocking PKCβ2 pathway with ruboxistaurin accelerated rhRLX-mediated inhibition in both proliferation of CFs and deposition of collagen.
In conclusion, relaxin can inhibit high glucose-associated cardiac fibrosis partly through PKCβ2 pathway. Further work should be done to fully understand intracellular mechanisms of relaxin's action to accelerate its clinical use.
松弛素是一种多效性激素,对许多器官具有内源性抗纤维化作用。我们之前已证明松弛素对心脏纤维化具有抑制作用。
本研究旨在探讨蛋白激酶C(PKC)β2在高糖条件下松弛素作用中的作用。
分离心脏成纤维细胞(CFs),使其暴露于高糖环境,并与重组人松弛素(rhRLX)一起孵育。蛋白质印迹分析显示,松弛素介导PKCβ2的总表达和转位减少,表明PKCβ2的下调参与了松弛素的作用。用鲁伯斯塔林阻断PKCβ2途径可加速rhRLX介导的对CFs增殖和胶原沉积的抑制。
总之,松弛素可部分通过PKCβ2途径抑制高糖相关的心脏纤维化。应进一步开展工作以充分了解松弛素作用的细胞内机制,从而加速其临床应用。